References
- Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90. https://doi.org/10.1016/S0140-6736(12)60367-5
- BIT Druginfo. Available from: https://www.druginfo.co.kr. Accessed 25 June, 2018.
- Drugs@FDA. Available from: https://www.accessdata.fda.gov/. Accessed 25 June, 2018.
- Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3-11. https://doi.org/10.1016/j.phrs.2014.03.002
- Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003;23(5):729-36. https://doi.org/10.1161/01.ATV.0000063385.12476.A7
- Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart 2007;93(8):1001-7. https://doi.org/10.1136/hrt.2006.088211
- Tousoulis D, Psarros C, Demosthenous M, et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol 2014;63(23):2491-502. https://doi.org/10.1016/j.jacc.2014.01.054
- Stroes ES, Thompson P D, Corsini A. et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-22. https://doi.org/10.1093/eurheartj/ehv043
- du Souich P, Roederer G, Dufour R. Myotoxicity of statins: mechanism of action 2017;175:1-16. https://doi.org/10.1016/j.pharmthera.2017.02.029
- Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007;100(9):1400-3. https://doi.org/10.1016/j.amjcard.2007.06.030
- Choi HK, Won EK, Choung SY. Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese Rats. Biomol Ther (Seoul) 2016;24(2):171-7. https://doi.org/10.4062/biomolther.2015.089
- Tomaszewski M, Stepien KM, Tomaszewska J, et al. Statin-induced myopathies. Pharmacol Rep 2011;63(4):859-66. https://doi.org/10.1016/S1734-1140(11)70601-6
- Sathasivam S. Statin induced myotoxicity. Eur J Intern Med 2012;23(4):317-24. https://doi.org/10.1016/j.ejim.2012.01.004
- Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2007;16(3):352-8. https://doi.org/10.1002/pds.1287
- El-Salem K, Ababneh B, Rudnicki S, et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve 2011;44(6):877-81. https://doi.org/10.1002/mus.22205
- Feng Q, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics 2012;13(5):579-94. https://doi.org/10.2217/pgs.12.11
- Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000;278(1):G156-64. https://doi.org/10.1152/ajpgi.2000.278.1.G156
- Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007;8(7):787-802. https://doi.org/10.2217/14622416.8.7.787
- Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63(1):157-81. https://doi.org/10.1124/pr.110.002857
- Hou Q, Li S, Li L, et al. Association between SLCO1B1 Gene T521C polymorphism and statin-related myopathy risk: A meta-analysis of case-control studies. Medicine (Baltimore) 2015;94(37):e1268 https://doi.org/10.1097/MD.0000000000001268
- Danik JS, Chasman DI, MacFadyen JG, et al. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J 2013;165(6):1008-14. https://doi.org/10.1016/j.ahj.2013.01.025
- Sessa M, Rafaniello C, Scavone C, et al. Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system? Expert Opin Drug Saf 2018;17(5):457-65. https://doi.org/10.1080/14740338.2018.1458837
- Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72. https://doi.org/10.1016/S0735-1097(02)02030-2
- de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292(11):1307-16. https://doi.org/10.1001/jama.292.11.1307
- Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from http://konos.go.kr/konosis/common/bizlogic.jsp. Accessed June 1, 2018.
- Zheng JS, Hu XJ, Zhao YM, et al. Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies. BMJ 2013;346:f3706. https://doi.org/10.1136/bmj.f3706
- Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Available from www.handbook.cochrane.org. Accessed June 1, 2018.
- Zhang BB, Xuan C, Deng KF, et al. Association between the MDR1 gene variant C3435T and risk of leukaemia: a meta-analysis. Eur J Cancer Care (Engl) 2013;22(5):617-25. https://doi.org/10.1111/ecc.12067
-
Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or
$I^{2}$ index? Psychol Methods 2006;11(2):193-206. https://doi.org/10.1037/1082-989X.11.2.193 - Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320(7249):1574-7. https://doi.org/10.1136/bmj.320.7249.1574
- Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54(17):1609-16. https://doi.org/10.1016/j.jacc.2009.04.053
- Linde R, Peng L, Desai M, et al. The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol 2010;2(2):77-84. https://doi.org/10.4161/derm.2.2.13509
- Santos PC, Gagliardi AC, Miname MH, et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68(3):273-9. https://doi.org/10.1007/s00228-011-1125-1
- Donnelly LA, Doney AS, Tavendale R, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 2011;89(2):210-6. https://doi.org/10.1038/clpt.2010.255
- Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statininduced myopathy-a genomewide study. N Engl J Med 2008;359:789-99. https://doi.org/10.1056/NEJMoa0801936
- Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011;21(5):280-8. https://doi.org/10.1097/FPC.0b013e328343dd7d
- Brunham LR, Lansberg PJ, Zhang L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012;12(3):233-7. https://doi.org/10.1038/tpj.2010.92
- Carr DF, O'Meara H, Jorgensen AL, et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther 2013;94(6):695-701. https://doi.org/10.1038/clpt.2013.161
- Mirosevic Skvrce N, Macolic Sarinic V, Simic I, et al. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. Pharmacogenomics 2015;16(8):803-15. https://doi.org/10.2217/pgs.15.47
- Liu JE, Liu XY, Chen S, et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol 2017;73(11):1409-16. https://doi.org/10.1007/s00228-017-2318-z
- Bakar NS, Neely D, Avery P, et al. Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study. Clin Pharmacol Ther 2018;104(1):178-87. https://doi.org/10.1002/cpt.887
- Ferrari M, Guasti L, Maresca A, et al. Association between statininduced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol 2014;70(5):539-47. https://doi.org/10.1007/s00228-014-1661-6
- Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16(12):873-9. https://doi.org/10.1097/01.fpc.0000230416.82349.90
- Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013;127(1):96-103. https://doi.org/10.1161/CIRCULATIONAHA.112.136101
- Jiang J, Tang Q, Feng J, et al. Association between SLCO1B1 -521T > C and -388A > G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis. Springerplus 2016;5(1):1368. https://doi.org/10.1186/s40064-016-2912-z
- Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001;120(2):525-33. https://doi.org/10.1053/gast.2001.21176
- Zair ZM, Eloranta JJ, Stieger B, et al. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 2008;9(5):597-624. https://doi.org/10.2217/14622416.9.5.597
- Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158(3):693-705. https://doi.org/10.1111/j.1476-5381.2009.00430.x
- Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011;10(3):373-87. https://doi.org/10.1517/14740338.2011.540568
- Vildhede A, Karlgren M, Svedberg EK, et al. Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Drug Metab Dispos 2014;42(7):1210-8. https://doi.org/10.1124/dmd.113.056309